A bicyclic peptide that targets a cancer integrin
Researchers report a bicyclic peptide isomer (10‑Mansa) that selectively inhibits integrin αvβ6 and shows prolonged tumor enrichment in preclinical work, highlighting how 3D peptide shape can make or break targeting.
Most drug stories sound like this: a molecule binds a target and changes a biological pathway.
This one is a little different. It is a story about shape.
Researchers report that two versions of what looks like “the same” bicyclic peptide behave like different molecules because they lock into different three-dimensional arrangements. One version binds a specific surface protein called integrin αvβ6; the other version largely does not.
The paper is Ansamer‑Controlled Bicyclic Peptides as Integrin αvβ6 Targeting Agents (Angewandte Chemie, 2026).
Start with the target: what is an integrin
Integrins are proteins on the surface of cells. You can think of them as part glue and part sensor.
They help cells attach to their surroundings, and they also pass signals back into the cell about what the environment is like. Because of that, certain integrins show up repeatedly in cancer biology and tissue remodeling.
Integrin αvβ6 is one of those “worth watching” targets. It is not a household name, but it is of interest because it can be unusually expressed in certain disease settings and it sits in a position where blocking it could change how cells interact with tissue.
Why a peptide (instead of an antibody or small molecule)
A lot of drug discovery is a tradeoff between size and precision.
Antibodies are large and often very specific, but they have their own delivery and tissue-penetration constraints.
Small molecules are small and often easier to deliver, but they can struggle to achieve high selectivity for some protein surfaces.
Peptides sit in between. A well-designed peptide can present a very specific “shape” to a target, while still being much smaller than an antibody. That is why integrin-binding peptides have been explored for years, especially when the goal is targeting.
What “bicyclic peptide” means here
A bicyclic peptide is a peptide that has been chemically constrained so it forms two loops.
The important consequence is not the word “bicyclic.” It is the constraint. When you lock a peptide into a tighter shape, you often reduce floppiness. That can improve binding because the peptide does not have to “find” the right shape every time it encounters the target.
In this work, the authors built a constrained peptide that includes an RGD motif, a short sequence that often shows up in integrin-binding designs.
The main result: same ingredients, different shapes, different behavior
Here is the punchline: the authors found two stable versions of the bicyclic peptide that do not readily convert into each other.
They call these separable conformational isomers ansamers. If you want a simpler translation, it is this: the peptide can settle into two different locked shapes, and those shapes behave differently.
In their experiments, the ansamer called 10‑Mansa showed potent, selective inhibition of integrin αvβ6. The other ansamer, 10‑Pansa, did not.
That is the kind of result medicinal chemists like because it turns “shape” into a design dial you can potentially control.
What else they report
The paper includes structural work supporting how the active ansamer binds, and it compares properties to a widely used linear integrin αvβ6 inhibitor peptide (A20FMDV). The authors describe faster cellular internalization and prolonged enrichment in tumor tissues in preclinical experiments.
It is worth reading this as a targeting and design story, not as a finished therapy story.
What this does and does not mean
What it does mean is that, for constrained peptides, the final three-dimensional arrangement can be as important as the sequence itself. Two “nearly identical” peptides can behave like different drugs if one is locked into a binding-competent shape.
What it does not yet mean is that integrin αvβ6 has a proven peptide therapeutic ready for clinical use. The hardest questions come next: delivery, safety, and whether changing this target improves outcomes in a specific disease context.
If this design approach generalizes, though, it is a useful idea for the broader peptide field: sometimes the lever is not a new target or a new sequence, but a new way to control peptide shape.